COEGIN Stock Overview
A biotechnology company, engages in the discovery and development of dermacosmetic products and drugs for the treatment of serious diseases associated with diabetes and cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Coegin Pharma AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 4.40 |
| 52 Week High | SEK 0 |
| 52 Week Low | SEK 0 |
| Beta | 1.03 |
| 1 Month Change | 2.33% |
| 3 Month Change | 10.00% |
| 1 Year Change | 54.28% |
| 3 Year Change | -87.88% |
| 5 Year Change | n/a |
| Change since IPO | -84.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| COEGIN | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 4.0% | 2.7% | 2.0% |
| 1Y | 54.3% | 1.3% | 5.2% |
Return vs Industry: COEGIN exceeded the Swedish Biotechs industry which returned 1.4% over the past year.
Return vs Market: COEGIN exceeded the Swedish Market which returned 5.8% over the past year.
Price Volatility
| COEGIN volatility | |
|---|---|
| COEGIN Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 12.9% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: COEGIN has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: COEGIN's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 1 | Jens Eriksson | coeginpharma.com |
Coegin Pharma AB, a biotechnology company, engages in the discovery and development of dermacosmetic products and drugs for the treatment of serious diseases associated with diabetes and cancer. Its products include AVX001 GEL drug candidate, which is in phase 2 clinical study for the treatment of actinic keratosis and in phase 1 clinical study for the treatment of basal cell carcinoma; AVX420 drug candidate in preclinical study for the indication of leukemia; FOL026, a peptide-based drug in preclinical study for the prevention of cardiovascular complications in diabetes; AVX420/FOL026 therapy in preclinical study for the treatment of kidney and liver fibrosis; and FOL005 for the treatment of stimulation of hair growth. The company was founded in 2005 and is based in Lund, Sweden.
Coegin Pharma AB Fundamentals Summary
| COEGIN fundamental statistics | |
|---|---|
| Market cap | SEK 89.70m |
| Earnings (TTM) | -SEK 23.78m |
| Revenue (TTM) | SEK 61.00k |
1,470x
P/S Ratio-3.8x
P/E RatioIs COEGIN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COEGIN income statement (TTM) | |
|---|---|
| Revenue | SEK 61.00k |
| Cost of Revenue | SEK 15.00k |
| Gross Profit | SEK 46.00k |
| Other Expenses | SEK 23.83m |
| Earnings | -SEK 23.78m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.17 |
| Gross Margin | 75.41% |
| Net Profit Margin | -38,985.25% |
| Debt/Equity Ratio | 0% |
How did COEGIN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/18 06:23 |
| End of Day Share Price | 2025/03/18 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Coegin Pharma AB is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kevin Sule | Redeye |